オクラシチニブ
オクラシチニブ 物理性質(zhì)
- 融點(diǎn) :
- 226-228°C
- 比重(密度) :
- 1.316±0.06 g/cm3(Predicted)
- 蒸気圧:
- 0Pa at 20-25℃
- 貯蔵溫度 :
- Refrigerator, Under inert atmosphere
- 溶解性:
- DMSO（わずかに）、メタノール（わずかに、超音波処理）
- 酸解離定數(shù)(Pka):
- 11.59±0.40(Predicted)
- 外見 :
- 個(gè)體
- 色:
- オフホワイトからペールベージュ
- InChI:
- InChI=1S/C15H23N5O2S/c1-16-23(21,22)9-11-3-5-12(6-4-11)20(2)15-13-7-8-17-14(13)18-10-19-15/h7-8,10-12,16H,3-6,9H2,1-2H3,(H,17,18,19)/t11-,12-
- InChIKey:
- HJWLJNBZVZDLAQ-HAQNSBGRSA-N
- SMILES:
- [C@@H]1(CS(NC)(=O)=O)CC[C@@H](N(C)C2N=CN=C3NC=CC3=2)CC1
- LogP:
- 1.38 at 35℃ and pH7
安全性情報(bào)
- リスクと安全性に関する聲明
- 危険有害性情報(bào)のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語 |
警告 |
| 危険有害性情報(bào) |
| コード |
危険有害性情報(bào) |
危険有害性クラス |
區(qū)分 |
注意喚起語 |
シンボル |
P コード |
| H302 |
飲み込むと有害 |
急性毒性、経口 |
4 |
警告 |
|
P264, P270, P301+P312, P330, P501 |
| H317 |
アレルギー性皮膚反応を起こすおそれ |
感作性、皮膚 |
1 |
警告 |
|
P261, P272, P280, P302+P352,P333+P313, P321, P363, P501 |
|
| 注意書き |
| P280 |
保護(hù)手袋/保護(hù)衣/保護(hù)眼鏡/保護(hù)面を著用するこ と。 |
|
| メーカー |
製品番號 |
製品説明 |
CAS番號 |
包裝 |
価格 |
更新時(shí)間 |
購入 |
|
富士フイルム和光純薬株式會社(wako)
|
W01COBQV-3088 |
Oclacitinib |
1208319-26-9 |
250mg |
￥37500 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式會社(wako)
|
W01COBQV-3088 |
Oclacitinib |
1208319-26-9 |
1g |
￥130000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式會社(wako)
|
W01FLC054379 |
N-Methyl-1-(trans-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide |
1208319-26-9 |
250mg |
￥144000 |
2020-09-21 |
購入 |
|
富士フイルム和光純薬株式會社(wako)
|
W01FLC054379 |
N-Methyl-1-(trans-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide |
1208319-26-9 |
1g |
￥363600 |
2020-09-21 |
購入 |
|
富士フイルム和光純薬株式會社(wako)
|
W01FLC054379 |
N-Methyl-1-(trans-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide |
1208319-26-9 |
5g |
￥1087200 |
2020-09-21 |
購入 |
オクラシチニブ 化學(xué)特性,用途語,生産方法
効能
鎮(zhèn)癢薬, 免疫抑制薬 (獣醫(yī)薬), ヤヌスキナーゼ(JAK)阻害薬
説明
Oclacitinib is an oral JAK inhibitor that is a drug approved by the U.S. Food and Drug Administration (FDA) for use in canine atopic dermatitis (AD). The U.S. FDA and the European Medical Association have approved a number of JAK inhibitors, including baricitinib, ruxolitinib, federatinib, tofacitinib, upadacitinib, oclacitinib, but some of these drugs are still being studied. Oclacitinib mainly shows activity against JAK1-dependent cytokines and also inhibits the function of JAK2-dependent cytokines. oclacitinib modifies the production of cytokines such as IL-4 and IL-13, which are crucial for B-cell proliferation and maturation in the pathogenesis of pemphigus foliaceus. Oclacitinib could interdict the effects of IL-6, a cytokine involved in the Toll-like receptor 4-originated signaling pathway in the bladder epithelial cells, and IL-8, which could theoretically contribute to a decreased defense against the urinary pathogens[1-4].
使用
Oclacitinib is a novel Janus kinase (JAK) inhibitor with activity against cytokines involved in allergy.
オクラシチニブ 上流と下流の製品情報(bào)
原材料
準(zhǔn)備製品
オクラシチニブ 生産企業(yè)
Global( 185)Suppliers
1208319-26-9(オクラシチニブ)キーワード:
- 1208319-26-9
- PF-03394197 (oclacitinib)
- Oclacitinib PF-03394197
- JAKi
- trans-N-Methyl-4-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-cyclohexanemethanesulfonamide
- CyclohexaneMethanesulfonaMide, N-Methyl-4-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-, trans-
- N-methyl-1-((1r,4r)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide
- N-Methyl-1-(trans-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide
- Oclacitinib
- PF 03394197
- Oclacitinib?, >98%
- PF03394197, >98%
- Oclactinib
- PF03394197; PF 03394197
- Oclacitinib USP/EP/BP
- Dimethyl biphenyl-4
- Apoquel
- Oclacitinib, 10 mM in DMSO
- N-Methyl-1-(trans-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide , Oclacitinib
- Oclacitinib: trans-N-Methyl-4-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclohexanemethanesulfonamide
- オクラシチニブ
- N-メチル-4α-[メチル(3H-ピロロ[2,3-d]ピリミジン-4-イル)アミノ]シクロヘキサン-1β-イルメタンスルホンアミド
- N-メチル-1-[(1r,4r)-4-[メチル({3H-ピロロ[2,3-d]ピリミジン-4-イル})アミノ]シクロヘキシル]メタンスルホンアミド